ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 3

Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC

March 7, 2025

Pedro C. Barata, MD, MSc, FACP , Moshe Ornstein, MD, Elizabeth Wulff-Burchfield, MD , Kathryn E. Beckermann, MD, PhD

Experts discuss the key findings from the final follow-up results of the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib in advanced renal cell carcinoma (RCC) and share perspectives on the clinical implications of these updated data, along with insights from other studies of note, including LITESPARK-003 (belzutifan plus cabozantinib) and LITESPARK-024 (belzutifan plus palbociclib).

EP. 1: Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

EP. 2: Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

Now Viewing

EP. 3: Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC

EP. 4: RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection

Video content above is prompted by the following:

The CheckMate 9ER trial established the efficacy of nivolumab plus cabozantinib in advanced RCC. Could you review the key findings from the final follow-up results and share your perspectives on the clinical implications of these updated data?
- Please feel free to highlight other studies of note:
  - LITESPARK-003 (belzutifan plus cabozantinib)
  - LITESPARK-024 (belzutifan plus palbociclib)